||Awaiting HTA submission from Applicant
||In combination with lenvatinib (Lenvima®) is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with lenvatinib compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE
|Pre-submission consultation with Applicant